Pitt-Hopkins Syndrome is not a well-known disorder, and there are not many treatments dedicated to alleviating the severe symptoms that children and adults with Pitt-Hopkins Syndrome suffer through. The purpose of this study is to create questionnaires tailored to Pitt-Hopkins syndrome. With the dearth of Pitt-Hopkins Syndrome research, more knowledge on the disorder and treatments to aid in daily functioning and quality of life can be attained through specialized symptom tracking questionnaires. During this study, the research team designed and finalized two Pitt-Hopkins Syndrome symptom specific questionnaires. Some of the most notable results included the discovery of the most severe symptoms: verbal expression, cognition, social activity, and attention. Additionally, through cross-correlational analysis interrelated symptom clusters that can be targeted for treatment have been discovered.

The purpose of this thesis is to analyze in-depth the current research on Autism Spectrum Disorder (ASD), outlining the prominently researched methods of treatment that have led to successful therapy for the ones being treated. Within this thesis, the definition of successful treatment of autistic individuals will be defined by how well the individuals can adapt to their employment opportunities and their own social lives. Success will be measured through the effectiveness of specific treatments, such as speech therapy and therapeutic-based diets, to better gauge the success rate of treatment for autistic individuals. The thesis itself will serve as a review of the currently proposed treatment methods, analyzing where the most successful treatments were derived from and then offering a summary conclusion on the overall scope of the research. Recommendations on future research will be made to encapsulate all the research provided through which a scholarly lens was applied. Overall, the best methods of treatment will involve both a dietary and occupational approach, so as to tackle any environmental or genetic origins of ASD. More specifically, through a combination of vitamin and mineral supplements to manage behavioral symptoms combined with Applied Behavioral Analysis techniques, ASD can be more effectively treated to improve an individual’s quality of life.

For my thesis I investigated an abnormal gut-derived metabolite of interest identified as 3-(3-hydroxyphenyl)-3-hydroxypropionic acid (HPHPA) that may serve as a potential biomarker for autism, and help us get a better understanding of the underlying mechanisms of this disorder. Currently a laboratory test for autism does not exist, posing severe consequences on individuals with autism. In order to gather research on my metabolite of interest and its connection to autism as well as disorders correlated with autism, I analyzed different pieces of scientific literature investigating HPHPA and compiled this data into a literature review.

Autism Spectrum Disorder (ASD) is an intricate neurodevelopmental disorder characterized by impaired social functioning and communication, repetitive behavioral patterns, and specialized interests (Olesova et al., 2020; Osredkar et al., 2023). Despite the efforts of modern science, the biological origin of ASD is unknown, and no known biomarker for ASD currently exists (Olesova et al., 2020; Osredkar et al., 2023). Indoxyl sulfate has been identified as a toxin associated with ASD and its related symptomology in addition to a number of other conditions, including chronic kidney disease, acute kidney injury, heart failure, Parkinson’s disease, and various mood disorders (Cao et al., 2015; Cassani et al., 2015; Karbowska et al., 2020; Zhao et al., 2013). This article will review what is currently known about indoxyl sulfate in relation to ASD and its comorbidities in an attempt to determine the validity of indoxyl sulfate as a potential biomarker for ASD. Articles for the purposes of this review were collected via Google Scholar, PubMed, and the ASU Library using key words such as “indoxyl sulfate,” “Autism,” and “indican,” and chosen based on relevancy. Through this review, indoxyl sulfate was identified as a potential physiological biomarker for a subset of ASD, with additional research required to verify the findings presented. The identification of a biomarker for ASD could change the current methods of testing for ASD, greatly improving our understanding and treatment of the disorder.

Organic light-emitting diodes (OLEDs) have been successfully implemented in various display applications owing to rapid advancements in material design and device architecture. Their success in the display industry has ignited a rising interest in applying OLEDs for solid-state lighting applications through the development of white OLEDs (WOLEDs). However, to enter the market as a serious competitor, WOLEDs must achieve excellent color quality, high external quantum efficiency (EQE) as well as a long operational lifetime. In this research, novel materials and device architectures were explored to improve the performance of single-stack WOLEDs. A new Pt-based phosphorescent emitter, Pt2O2-p2m, was examined as a single emissive emitter for the development of a stable and efficient single-doped WOLED. A bilayer structure was employed to balance the charges carriers within the emissive layer resulting in low efficiency roll-off at high brightness, realizing a peak EQE of 21.5% and EQEs of 20% at 1000 cd m-2 and 15.3% at 7592 cd m-2. A novel phosphorescent/fluorescent, or hybrid, WOLED device architecture was also proposed. To gather a thorough understanding of blue fluorescent OLEDs prior to its use in a WOLED, a study was conducted to investigate the impact of the material selection on the device performance. The use of an anthracene type host demonstrated an improvement to the operational stability of the blue OLED by reducing the occurrence of degradation events. Additionally, various dopant concentrations and blocking materials revealed vastly different efficiency and lifetime results. Finally, a Pd (II) complex, Pd3O8-Py5, with efficient amber-colored aggregate emission was employed to produce a WOLED. Various host materials were investigated to achieve balanced white emission and the addition of an interlayer composed of a high triplet energy material was used to reduce quenching effects. Through this strategy, a color stable WOLED device with a peak EQE of 45% and an estimated LT95 over 50,000 hours at 1000 cd m-2 was realized. The comprehensive performance of the proposed device architecture competes with WOLED devices that are commercially available and reported within the literature domain, providing a strong foundation to further advance the development of highly efficient and stable single-stack WOLEDs.

Over the past three decades, significant progress in the development of organic light-emitting diodes (OLEDs) has been achieved, enabling OLEDs to become a main component in state-of-the-art displays and next generation solid-state lighting. As this technology advances, it is highly desirable to further improve the device efficiency and operational stability to drive the success of OLEDs in future display and lighting applications. This dissertation aims at developing novel organic emitting materials covering visible and near-infrared (NIR) emissions for efficient and table OLEDs. Firstly, a series of tetradentate Pd(II) complexes, which have attractive phosphorescent aggregate emission performance especially at high brightness level in device settings, have been developed. The luminescent lifetime of Pd(II) complex aggregates was demonstrated to be shorter than 1 μs with a close-to-unity photoluminescence quantum yield. Moreover, a systematic study regarding structure-property relationship was conducted on four tetradentate Pd(II) complexes, i.e., Pd3O3, Pd3O8-P, Pd3O8-Py2, and Pd3O8-Py5, featuring aggregate emission. As a result, an extremely efficient and stable OLED device utilizing Pd3O8-Py5 was achieved. It demonstrated a peak external quantum efficiency (EQE) of 37.3% with a reduced efficiency roll-off retaining a high EQE of 32.5% at 10000 cd m-2, and an estimated LT95 lifetime (time to 95% of the initial luminance) of 48246 h at 1000 cd m-2. Secondly, there is an increasing demand for NIR OLEDs with emission spectra beyond 900 nm to expand their applications in biometric authentication, night vision display, and telecommunication, etc. A stable and efficient NIR Pt(II) porphyrin complex named PtTPTNP-F8 was developed, and exhibited an electroluminescent spectrum at 920 nm. By carefully choosing the host materials, an PtTPTNP-F8 based NIR OLED achieved a EQE of 1.9%. Furthermore, an PtTPTNP-F8 OLED fabricated in a stable device structure demonstrated extraordinary operational stability with LT99 of >1000 h at 20 mA cm-2. Lastly, a series of imidazole-based blue Pt(II) complexes were developed and studied. Results indicated that structural modification of ligand molecules effectively tuned the emission spectral wavelength and bandwidth. Two blue complexes, i.e., Pt2O2 P2M and Pt2O2-PPy5-M, emitting at 472 and 476 nm respectively, exhibited narrow-band emission spectra with a full width at half maximum of 16 nm.